FDA Approved: INGREZZA — Supplemental Application (Neurocrine Biosciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INGREZZA (valbenazine) submitted by Neurocrine Biosciences. The action updates the drug's labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

SUPPL AP for INGREZZA (VALBENAZINE)